Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Biotech
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Days after inking a $1.4 billion buyout, AbbVie has put up the same in biobucks to secure options on multispecific T-cell engagers.
Nick Paul Taylor
Oct 31, 2024 10:00am
Crescent inks GlycoMimetics merger, securing listing and $200M
Oct 29, 2024 10:20am
Shattuck axes CD47 program, cuts 40% of staff over weak data
Oct 1, 2024 8:22am
AstraZeneca extends AI immuno-oncology R&D pact with Immunai
Sep 26, 2024 9:00am
Genentech to close cancer immunology research department
Aug 16, 2024 11:08am
ALX's fizzling CD47 response rate sends stock spiraling down
Aug 1, 2024 5:34am
